Stay updated on Pembrolizumab in EOC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in EOC Clinical Trial page.

Latest updates to the Pembrolizumab in EOC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe page’s software/version label was updated from Revision v3.5.2 to v3.5.3, indicating a minor site release without altering the clinical trial study details.SummaryDifference0.1%

- Check26 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0 from the page.SummaryDifference0.1%

- Check55 days agoChange DetectedPage revision updated to v3.5.0, replacing the previous v3.4.3.SummaryDifference0.1%

- Check62 days agoChange DetectedRevision label updated to v3.4.3 (previously v3.4.2). This appears to be a minor site version change and does not modify study data or content.SummaryDifference0.1%

- Check91 days agoChange DetectedFallopian tube cancer added as a condition and the page updated to version 3.4.2; the government funding status notice has been removed.SummaryDifference0.5%

- Check98 days agoChange DetectedA site-wide government funding/status notice was added and the page version updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab in EOC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in EOC Clinical Trial page.